1661P Efficacy and safety of RP1 + nivolumab (nivo) in patients with non-melanoma skin cancer (NMSC)
Year: 2025
Type: article
Source: Annals of Oncology
Institutions: Essen University Hospital, University of Duisburg-Essen, Roswell Park Comprehensive Cancer Center, Duke University, Duke Cancer Institute, Weill Cornell Medicine, Institute of Cancer Research, National Institute for Health and Care Research, NIHR Biomedical Research Centre at The Royal Marsden and the ICR, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Banner MD Anderson Cancer Center, West Cancer Center, Intermountain Medical Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, University of Washington, Fred Hutch Cancer Center, University of Cincinnati, University of Cincinnati Medical Center, Institut Gustave Roussy, Fondation Gustave Roussy, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Centre Léon Bérard, Replimune Group, Inc. (United States), University of Iowa, University of Iowa Health Care, University of Iowa Holden Comprehensive Cancer Center
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415941225